Cybin

Cybin was co-founded, in 2019, by Paul Galvine (COO), John Kanakis (Director and SVP of Business Development) and Eric So (President) with Doug Drysdale as CEO. Cybin is a Toronto-listed life sciences company, focused on progressing psychedelic therapies by utilizing proprietary drug discovery platforms combined with novel delivery and formulation technologies, that went public in November 2020 (NEO: CYBN) after they announced the completion of a reverse take-over with Clarmin Explorations.

Depression affects hundreds of millions of people globally. In the US it is estimated that 7% (17 million) of the adult population had an episode of MDD in 2017. There is no doubt that the pandemic has exasperated this problem significantly and recently the UK estimated the pandemic had added an additional 1.3% increase in adults suffering from MDD. There have been no major breakthrough drug treatments in psychiatry for decades and now there is an enormous opportunity for psychedelics in this sector. A recent study by Johns Hopkins (Nov 2020) trialling the use of Psilocybin in patients with MDD found 71% indicated a clinically significant response and 54% met the criteria for remission for depression. Alongside traditional treatments there is sufficient space for innovative new psychedelic therapies – with nuances on dosing, formulation, etc and even a small cut of this market would lead to strong US and global sales.

One of only four companies with active clinical trials - Cybin is currently developing CYB001 – a psilocybin sublingual (under the tongue) film and has just entered into a Phase 2a (dosage) clinical trial in Jamaica to study psilocybin use for major depressive disorder (MDD). The Phase 2b trial will include 120 patients taking four doses of the film containing psilocybin over a four-month period. As of May 18, 2021, Cybin was granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder. These Phase 2a trials are now underway and results are due in mid-2021. Cybin expects to file an investigational drug application (IND) and start a Phase 2b (efficacy) clinical trial in US shortly.

Cybin has two other product programs; deuterated tryptamines and phenethylamines, from which other candidates could enter the clinic as well. Clinical entry of the first deuterated tryptamine CYB003 (short acting tablet) anticipated at the end of 2021 and clinical entry of the second deuterated tryptamine CYB004 (delivery – inhalation - focusing on social anxiety disorder and generalized anxiety disorder) due 1H 2022.

In June 2021 Cybin announced that it will co-sponsor a randomized, placebo-controlled trial of psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The study will aim to treat symptoms of depression, anxiety and post-traumatic stress among frontline healthcare professionals.

As of December 2020, Cybin signed a definitive agreement to acquire Adelia Therapeutics as part of its commitment to strategic growth. Adelia Therapeutics (based in Boston) broadens out Cybin's access to novel therapeutics, delivery methods, and therapeutic regimens. This acquisition means that Cybin has access to molecule-tweaking technology that could lead to better dosing profiles and more solidity around IP (this is important as traditional psychedelics will probably no longer have compound patent protection). Drug delivery can be important for speed of onset and scalability for real-world usage.

Cybin also partnered with Kernel – technology leader in neuroimaging hardware and software – allowing them to record and to quantify brain activity during a psychedelic experience in real time – giving an extra dimension in its research to develop breakthrough psychedelic treatments for mental health.

Cybin currently have 12 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.

Currently Listed on Canadian NEO Exchange: CYBN and the USOTC Venture Exchange. Cybin are MJDS eligible for a Tier 1 US exchange listing and this is expected to take place imminently.

Event	Timing	Focus
Initiation of Phase 2a study of sublingual film CYB001	2Q21	Major Depressive Disorder
Completion of Phase 2a study of sublingual film CYB001	Mid – 21	Major Depressive Disorder
IND filing with the FDA for sublingual film CYB001	Mid – 21	Major Depressive Disorder
Initiation of Phase 2b study of sublingual film CYB001 in US	End of 2021	Major Depressive Disorder
Clinical entry of first deuterated tryptamine candidate CYB003	End of 2021	Alcoholic Use Disorder
Data readout from global Phase 2b study of CYB001	2H22	Major Depressive Disorder
Clinical entry of second deuterated tryptamine candidate CYB004	1H22	TRPDs
Potential clinical entry of first Phenethylamine drug candidate - CYB005	End of 2022	Psychiatry/neurology

Financial key performance indicators

Quarterly EPS	Q1	Q2	Q3	Q4
2021E	(0.04)A	(0.02)A	(0.06)A	(0.04)
2022E	(0.04)	(0.04)	(0.05)	(0.05)

Cash runway lasts 24-36 months.

Shareholders/Funding

Funding: The Company closed, in Oct 2020, a C$45 million subscription receipt financing in relation to its reverse takeover transaction, which marked the largest subscription receipt financing in the Canadian psychedelic sector. In Jan 2021, they raised C$30m through a highly successful bought deal – which was upsized from original $20m size. They have raised a total of nearly C$90m to date. Investors include several Blue-Chip US Investors including Janus Henderson, LifeSci Ventures and RA Capital.

Analyst coverage

Canaccord Genuity	BUY	Price Target: C$8.00
Stifel Nicolaus	BUY	Price Target: C$15.00
Roth Capital	BUY	Price Target: C$10.00

Stock currently C$2.54